Who are Kymera Therapeutics, Inc.'s main suppliers?

Kymera Therapeutics, Inc. (KYMR) key suppliers include: C4 Therapeutics, Inc., C4 Therapeutics, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Monte Rosa Therapeutics, Inc. and 6 more. View the full supplier network at chainsifter.com/chain/KYMR.

Who are Kymera Therapeutics, Inc.'s major customers?

Kymera Therapeutics, Inc. (KYMR) key customers include: SANOFI, GENZYME-CORPORATION, Monte Rosa Therapeutics, Inc., Sanofi, Sanofi and 2 more. View the full customer network at chainsifter.com/chain/KYMR.

What sector is Kymera Therapeutics, Inc. in?

Kymera Therapeutics, Inc. (KYMR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

KYMR Supply Chain: Kymera Therapeutics, Inc. Supplier List & 20 Relationships

11Suppliers

7Customers

2Debt Items

20Related Chains

Kymera Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CCCC	C4 Therapeutics, Inc.	72%	hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a…
CCCC	C4 Therapeutics, Inc.	72%	Reciprocal relationship from CCCC graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of th…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of th…
GILD	Gilead Sciences, Inc.	72%	hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a…
GLUE	Monte Rosa Therapeutics, Inc.	72%	Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of the…
JNJ	Johnson & Johnson	72%	hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a…
NRIX	Nurix Therapeutics, Inc.	72%	hese manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there a…
NRIX	Nurix Therapeutics, Inc.	72%	Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: hese manufacturers on a purchase or…
SNYNF	Sanofi	72%	ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of th…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: ch on the targets, and Vertex was…

Kymera Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
SANOFI	SANOFI	92%	Under the Sanofi Agreement, we granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration
GENZYME-CORPORATION	GENZYME-CORPORATION	90%	On July 7, 2020, we entered into a collaboration agreement, or the Original Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biologica…
GLUE	Monte Rosa Therapeutics, Inc.	72%	Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t…
SNYNF	Sanofi	72%	ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of th…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product c…
VRTX	Vertex Pharmaceuticals Incorporated	72%	ess overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to …
VRTX	Vertex Pharmaceuticals Incorporated	72%	Reciprocal relationship from VRTX graph: Reciprocal relationship from KYMR graph: ess overall. Because of the numerous risks and uncertainties associated with product development, we are unable to pr…

Kymera Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
KYMR-DEBT	Debt stack $80.5M	90%	Market cache reports total debt of $80.5M.
KYMR-DEBT-10596	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.

Kymera Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Kymera Therapeutics, Inc..

Kymera Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
KYMR-OWNER-AVORO-CAPITAL-ADVISORS-LLC	Avoro Capital Advisors LLC	90%	13F overlay lists Avoro Capital Advisors LLC as top holder; 262 tracked holders.

Kymera Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
BIOA	BioAge Labs, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
WHWK	Whitehawk Therapeutics, Inc.	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
BNBX	BNB Plus Corp.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2

Kymera Therapeutics, Inc. Supply Chain